Indeed, cultivars targeting TNFα, IL-6, IL-1β and causing concerted and significant downregulation of the rheumatoid arthritis pathway, pending thorough verification and clinical validation, may present a novel and promising natural resource for RA treatments and management of other TNFα, IL-6, IL-1β-mediated diseases. This evidence concerns the gene TNF and rheumatoid arthritis.